Yearly Archives: 2023

Pharmacy press We were asked to respond to suggestions that the Independent Prescribing (IP) Pathfinder Programme has been under-funded and pharmacies which had previously expressed interest are pulling out as a result. Our Director of NHS Services, Alastair Buxton, said: “The proposed funding and other aspects of the IP pathfinder programme has raised concerns for [...]

The post Fee for independent prescribing under pathfinder programme appeared first on Community Pharmacy England.

Following discussions between Community Pharmacy England and the Department of Health and Social Care (DHSC) regarding medicine pricing issues reported by pharmacy owners, the Department has today (19/09/2023) announced the following initial list of price concessions for September 2023: Drug Pack size Price concession Acamprosate 333mg gastro-resistant tablets 168 £23.67 Aciclovir 800mg tablets 35 £3.81 [...]

The post September 2023 Price Concessions 1st Update appeared first on Community Pharmacy England.

The Times, The Independent, Evening Standard, Daily Mail, The Telegraph In response to the Nuffield Trust and The King’s Fund’s publication of ‘A Vision for Community Pharmacy’ (a report we commissioned), we shared the following statement with national media. Chief Executive Janet Morrison said: “Community pharmacies are critical to the health of the nation but [...]

The post Our response to the vision report in national press appeared first on Community Pharmacy England.

Nuffield Trust and The King’s Fund have today published ‘A Vision for Community Pharmacy’, setting out how community pharmacies’ role in healthcare could be expanded over the next decade, with the right investment and support. In their Vision, the think tanks describe a transformation of the community pharmacy sector, focusing on how pharmacies can help [...]

The post Leading health think tanks set out vision for pharmacies appeared first on Community Pharmacy England.

Department of Health and Social Care (DHSC) has issued a medicine supply notification for Estradiol valerate/medroxyprogesterone acetate (Indivina®) 1mg/5mg tablets. MSN/2023/084 Tier 2 – medium impact Date of issue 14th September 2023 Estradiol valerate/medroxyprogesterone acetate (Indivina®) 1mg/5mg tablets are out of stock until w/c 11th December 2023. Alternative continuous combined hormone replacement therapies (HRT) containing [...]

The post Medicine Supply Notification: Estradiol valerate/medroxyprogesterone acetate (Indivina® ) 1mg/5mg tablets appeared first on Community Pharmacy England.